Plain-English translation of NCT07581184 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new radioactive medication called [225Ac]Ac-AKY-2519 designed to treat metastatic castration-resistant prostate cancer—a type of advanced prostate cancer that has spread to other parts of the body and no longer responds to hormone-blocking drugs. The medication works by targeting a specific protein (B7-H3) found on cancer cells and delivering radioactive particles directly to them. This is an early-phase trial to determine if the medication is safe and whether it helps slow or shrink the cancer.
Men with advanced prostate cancer that has spread and become resistant to standard hormone treatments need new options. This trial exists to see if the new treatment can effectively target and kill these hard-to-treat cancer cells while being tolerable for patients.
You likely qualify if…
You likely don't qualify if…
You would receive IV infusions of the experimental medication at a clinic or hospital. The study has two main phases: first, researchers test different doses in small groups to find the safest and most effective dose; then, additional patients are enrolled at the selected doses to gather more information. You would have blood tests, imaging scans, and clinical evaluations to monitor how you respond to the treatment and watch for any side effects.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
United States